BioSpace News Archive

In the United States, one out of every five adults has a disability, according to a new study published by the Centers for Disease Control and Prevention.

Use of orthopedic imaging equipment is highly crucial for diagnosing and treating injuries, diseases, and ailments related to bone, cartilage, and associated portions of the body.

DUBAI, United Arab Emirates, Despite the COVID-19 dilemma, the global Viral Vector Development Market, which was forecast to be worth US$ 534 million in 2021, is expected to increase to US$3.2 billion by 2032, at a CAGR of 18.2% through 2032.

Albany NY, United States: Repair of wounds and tissues often involves the passage of threads, also known as sutures, through a dense osseous tunnel.

A shaking incubator is an instrument that performs agitation at a specific speed under a temperature-controlled environment in order to provide optimum conditions for the growth of cells and tissue in a culture.

Calithera Biosciences, Inc., a clinical-stage, precision oncology biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 18,518,519 shares of its common stock at a price to the public of $0.54 per share.

Transcenta Holding Limited announces the preclinical data of TST005, a bifunctional fusion protein of PD-L1/TGF-βRII, will be presented as a poster at the upcoming 2022 American Association for Cancer Research Meetings, taking place from April 8th to April 13th in New Orleans via in person or virtual attendance.

Ascletis Pharma Inc. announces the completion of patient enrollment in the Phase II clinical trial of ASC42 for chronic hepatitis B indication.

Design Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for degenerative genetic disorders, announced that it has completed dosing in the first single ascending dose cohort of its Phase 1 clinical trial of DT-216 in patients with Friedreich ataxia.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the fourth quarter and full year ended December 31, 2021.